1100095-09-7 Usage
General Description
The chemical compound (3-(pyrrolidin-1-ylMethyl)phenyl)boronic acid is a boronic acid derivative with a pyrrolidinylmethyl group attached to a phenylboronic acid moiety. It is commonly used in organic chemistry as a reagent for Suzuki-Miyaura coupling reactions, which are widely employed in the synthesis of biaryls and other organic compounds. The pyrrolidinylmethyl group provides steric hindrance and can also act as a directing group in organic reactions, allowing for selective functionalization of specific positions on aromatic rings. (3-(pyrrolidin-1-ylMethyl)phenyl)boronic acid has garnered interest in medicinal chemistry due to its potential as a building block for the synthesis of biologically active molecules and pharmaceuticals. Additionally, it has shown promise as a ligand in catalysis and as a fluorescent probe for the detection of certain biomolecules.
Check Digit Verification of cas no
The CAS Registry Mumber 1100095-09-7 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,1,0,0,0,9 and 5 respectively; the second part has 2 digits, 0 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 1100095-09:
(9*1)+(8*1)+(7*0)+(6*0)+(5*0)+(4*9)+(3*5)+(2*0)+(1*9)=77
77 % 10 = 7
So 1100095-09-7 is a valid CAS Registry Number.
1100095-09-7Relevant articles and documents
8-SUBSTITUTED QUINOLINES AND RELATED ANALOGS AS SIRTUIN MODULATORS
-
Page/Page column 120, (2010/09/18)
Provided herein are 8-substituted quinolines and related analogues as sirtuin-modulating compounds of Structural Formula (I) and methods of use thereof. The sirtuin-modulating compounds may be used for increasing the lifespan of a cell, and treating and/or preventing a wide variety of diseases and disorders including, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing as well as diseases or disorders that would benefit from increased mitochondrial activity. Also provided are compositions comprising a sirtuin-modulating compound in combination with another therapeutic agent.
